Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
09:06
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

WFH 2014 World Congress

 

11-15 May 2014 Melbourne
FAQs
   
Discussion forum - WFH 2014 World Congress
    Topic - Clotting Factor Concentrates

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
High-purity, plasma-derived, pasteurized Factor VIII concentrate in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance  Robert Klamroth 1      5/2/2014 2:21:00 PM  
Validation of a population pharmacokinetic model of recombinant factor VIII in boys with Haemophilia A  John Roy 1      4/23/2014 9:10:00 PM  
Products registry  Mark Brooker 1      4/23/2014 8:55:00 PM  
Recombinant factor IX (BAX326) in pediatric PTPs with hemophilia B: a prospective clinical trial  Miranda Chapman 1      4/23/2014 4:08:00 PM  
Is switching from a pdFIX (Immunine) to a rFIX (Bax326) safe?  Borislava Pavlova 1      4/23/2014 3:58:00 PM  
Safety and efficacy of a new high purity factor X concentrate in subjects with factor X deficiency undergoing surgery  Miranda Norton 1      4/23/2014 2:00:00 PM  
Recombinant or plasma derived factor concentrates attitudes of patients in Germany  Christina Mondorf 1      4/22/2014 6:30:00 PM  
In-vivo efficacy of human recombinant Factor IX produced by the Hepatoma cell line HuH-7  Nathalie ENJOLRAS 1      4/22/2014 1:46:00 PM  
Assessment of Incremental Recovery Over Time in Postauthorization Safety Surveillance Study (PASS) of Hemophilia A Patients Switching from Moroctocog alfa or Other Factor VIII Products to Moroctocog alfa Albumin Free Cell Culture ( AF-CC)  Joan Korth-Bradley 1      4/16/2014 5:36:00 PM  
Safety and efficacy of Factor VIIa-CTP, a novel long-acting coagulation factor proposing an improved prophylactic and on demand treatment of hemophilic patients in preparation for First in Human Study  Gili Hart 1      4/13/2014 1:32:00 PM  
Factor VIIa-CTP, a novel long-acting coagulation factor proposing an improved prophylactic and on demand treatment of hemophilic patients, extensive invitro characterization in preparation for First in Human Study  Gili Hart 1      4/13/2014 1:29:00 PM  
The role of VWF in FVIII/VWF concentrates: biochemical characterization of three different plasma-derived factor VIII products  Raimondo De Cristofaro 1      4/13/2014 7:39:00 AM  
Pharmacokinetics (PK) of recombinant and plasma-derived factor IX (FIX) products in pediatric patients with severe hemophilia B  Kim Nagel 1      3/17/2014 6:18:00 PM  
Successful Treatment of Glanzmanns Thrombasthenia with Recombinant Activated Factor VII NovoSeven  Bijan Keikhaei 1      3/13/2014 10:35:00 PM  
In-vitro characterisation of the first therapeutic factor V concentrate  Andrew Lawrie 1      3/4/2014 2:58:00 PM  
       




Most viewed poster for this congress
Poster: 1
Visits: 2526
Title: A WEB SITE TO IMPROVE MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT: RESULTS AT 2 YEARS
Authors: Annarita Tagliaferri ,
Centre: Centro di Riferimento Regionale per la cura dellEmofilia

Poster most viewed in this topic
Poster: 1
Visits: 525
Title: Donor Variation in the Interaction of Activated Recombinant Factor VII (rFVIIa) with Human Platelets and Detection of a High rFVIIa Binding Subpopulation
Authors: Michael Dockal ,
Centre: Baxter Innvoations GmbH


 








PosterSessionOnline
Logo Draft
 
Logo Cert